JS113 / Wigen Biomedicine, Shanghai Junshi Biosci - LARVOL DELTA

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=14 | Terminated | Sponsor: Suzhou Junjing BioSciences Co., Ltd. | N=162 ➔ 14 | Recruiting ➔ Terminated; Due to the adjustment of the R&D strategy, Suzhou Junjing Biosciences Co., Ltd. decided to terminate this study in September 2023

Enrollment change • Monotherapy • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. (PubMed, Bioorg Med Chem) - "This review delves into the current clinical status, efficacy, safety profiles, and regulatory approvals of third-generation EGFR TKIs, including Osimertinib, Lazertinib, Furmonertinib, Aumolertinib, Rezivertinib, Befotertinib, Sunvozertinib...Notable fourth-generation candidates such as TQB3804, BPI-361175, BDTX-1535, WJ13404, QLH11811, H002, HS-10375, BBT-207, JIN-A02, and HS-10504 are highlighted for their potential to overcome the C797S mutation...By evaluating the therapeutic potential and limitations of these EGFR TKIs, this review aims to guide future research in the management of EGFR-mutant NSCLC. This acts as guiding beacon for the strategic design and development of third and fourth generation EGFR-TK inhibitors to overcome the drug resistance hurdles in the development of EGFR-TK inhibitors."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=162 | Recruiting | Sponsor: Suzhou Junjing BioSciences Co., Ltd.

Metastases • Monotherapy • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor